PDCD1 and colorectal cancer: The prognosis and drug targets of the drug; inhibiting the “eraser” (demethylase_FTO, ALKBH5) may increase the sensitivity of colorectal cancer patients to immune checkpoint therapy and reduce resistance after the anti-PD-1/PD-L1 therapy.